SEC Company Response from Keros Therapeutics, Inc. (KROS) (CIK 0001664710) (KROS) — Apr 3, 2020
Keros Therapeutics, Inc. (KROS) (CIK 0001664710)
Date: April 3, 2020 · CIK: 0001664710 · Accession: 0001193125-20-098325
AI Filing Summary & Sentiment
File numbers found in text: 333-237212
Letter
KEROS THERAPEUTICS, INC.
99 Hayden Avenue, Suite 120, Building E
Lexington, Massachusetts 02421
April 3, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Julia Griffith
Mr. Dietrich King
Ms. Christie Wong
Mr. Brian Cascio
RE: Keros Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-237212
Acceleration Request
Requested Date: Tuesday, April 7, 2020
Requested Time: 4:00 p.m. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Keros Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Tuesday, April 7, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant’s counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Ryan Sansom and Esther Cho of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Ryan Sansom of Cooley LLP, counsel to the Registrant, at (617) 937-2335, or in his absence, Esther Cho at (617) 937-2354.
[Signature Page Follows]
Very truly yours,
KEROS THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP KEROS THERAPEUTICS, INC. 99 Hayden Avenue, Suite 120, Building E Lexington, Massachusetts 02421 April 3, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Julia Griffith Mr. Dietrich King Ms. Christie Wong Mr. Brian Cascio RE: Keros Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-237212 Acceleration Request Requested Date: Tuesday, April 7, 2020 Requested Time: 4:00 p.m. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Keros Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective on Tuesday, April 7, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant’s counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes each of Ryan Sansom and Esther Cho of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Ryan Sansom of Cooley LLP, counsel to the Registrant, at (617) 937-2335, or in his absence, Esther Cho at (617) 937-2354. [Signature Page Follows] Very truly yours, KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Name: Jasbir Seehra, Ph.D. Title: Chief Executive Officer cc: Jennifer Lachey, Keros Therapeutics, Inc. Marc A. Recht, Cooley LLP Ryan S. Sansom, Cooley LLP Brandon Fenn, Cooley LLP Esther Cho, Cooley LLP Peter N. Handrinos, Latham & Watkins LLP Nathan Ajiashvili, Latham & Watkins LLP [Company Signature Page to Acceleration Request]